The longer to report data the better - human clinical trials are not like reporting on a mines drill samples...
The fact we keep opening more trials shows how important Paxalisib is and in most cases these trials are funded by the trial partner meaning they bare the cost and they can decide when to report on or terminate a study... as such they will follow the science and will not be concerned for others reporting schedules. What's really interesting to me is - none have terminated a study and more studies keep opening up!
We are hoping for around 4 - 6 reports across studies this next quarter so it might get interesting this summer.
As always it takes years of hard work to become an overnight success - the loudest squeals seem come from those with the least amount of time on the train.
